Blood stream infections (BSIs) are a serious problem in patients with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation (ASCT). We evaluated the clinical utility of molecular diagnosis for the management of BSIs in such patients. We prospectively performed a polymerase chain reaction (PCR) analysis of microbial DNA in blood samples from 10 consecutive patients with hematological malignancies at least once a week for one month after ASCT. In total, 51 and 54 samples were analyzed by bacterial and fungal PCR assays, respectively. Bacteria were detected in 24 samples from 8 patients by PCR, but in only 2 samples from one patient by blood culture. Notably, the bacteria detected in at least half of the 24 samples were considered to have originated from the oral cavity. Fungi were detected in 5 samples from 3 patients by PCR, but not by blood culture. Most cases with positive PCR results were manageable with empirical antimicrobial therapy without disclosure of DNA data. Our DNA analyses did not directly contribute to management of BSIs, but did provide valuable microbiological evidence for the patients. Additionally, oral management appears to require a critical re-evaluation to reduce the occurrence of BSIs in ASCT recipients.
Introduction
Allogeneic hematopoietic stem cell transplantation (ASCT) offers the chance of cure for patients with hematologic malignancies. However, blood stream infections (BSIs) are major causes of morbidity and mortality for patients undergoing ASCT [1] . Therefore, successful management of these infectious complications is essential to further improve the clinical outcome of such patients. BSIs commonly develop early after ASCT despite the use of prophylactic anti-infective drugs [1] [2] . However, conventional blood culture (BC), which is the gold standard for identifying causative pathogens, has a low isolation rate and is very time-consuming [3] . At present, there is no solution for BSI management other than empirical antimicrobial therapy despite the lack of microbiological evidence in a majority of ASCT recipients. On the other hand, polymerase chain reaction (PCR)-based analysis of microbial DNA is a promising tool for the sensitive and rapid detection of etiological organisms [3] [4] . PCR assays are reportedly useful in managing febrile neutropenia in patients with hematologic disorders [5] [6] . To our knowledge, however, these molecular techniques have not been well evaluated in hematologic patients undergoing ASCT.
In this study, we prospectively applied an original PCR assay to find causative organisms in peripheral blood (PB) samples of patients with hematologic malignancies who had received ASCT, and we evaluated its clinical usefulness for managing BSIs. Our DNA data provide valuable microbiological information for the management to reduce the occurrence of BSIs in ASCT recipients.
Materials and Methods

Patients and Definitions
Patient characteristics are shown in Table 1 . Ten consecutive patients (median age, 44 yr.; range, 19 -62 yr.) with hematologic malignancies who had undergone ASCT in our institution were enrolled. This prospective study was approved by the Human Research Ethics Committee of Mie University (Tsu, Japan), and was in accordance with the current version of the Helsinki Declaration. Written informed consent was obtained from all patients recruited. Eight patients received total body irradiation (TBI)-based conventional preconditioning regimen and 2 received reduced-intensity preparative regimens. Graft-versushost disease (GVHD) prophylaxis was either cyclosporine or tacrolimus, which was combined with a short course of methotrexate. All patients were housed in rooms equipped with a high-efficiency particulate air system, and standard precautions were used for all patients care. They received antibacterial prophylaxis with fluoroquinolone and antifungal prophylaxis with mold-active azoles, such as itraconazole (ITCZ) or voriconazole (VCZ), with temporary use of micafungin during the preconditioning period. Prophylaxis against herpes virus infection was also given with acyclovir. We performed PCR analyses of bacteria and fungi from fresh PB samples at least once weekly for the first 30 days after ASCT. Diagnosis of invasive fungal disease was made according to the revised classification of with or without aminoglycoside (arbekacin), and when a substantial mucosal injury occurred, a glycopeptide [vancomycin (VCM) or teicoplanin] was added [8] . As a surrogate marker for mucosal injury, we adopted the severity of stomatitis and diarrhea according to the National Cancer Institute Common Terminology Criteria for Adverse Events Scales (NCI-CTCAE) [9] . PCR results were not shared with the physicians, but were disclosed if fever continued despite empirical antimicrobial treatment and if the physician requested them. For febrile episodes, BC was performed as necessary. Blood samples were cultured in an auto- 
Molecular Detection of Bacteria and Fungi
PCR-based molecular detection of bacterial and fungal DNA was designed to and n-Fung-R: 5'-CCCCGACCGTCCCTATTAAT-3'). The wide-range fungal PCR was simultaneously performed during second-round PCR to detect the small amounts of fungal DNA that could not be detected by first-round PCR and the sequence identified. We validated that the gene products amplified by the susceptibility primers were indeed derived from fungal DNA and obtained the same level of sensitivity to detect fungal species other than Candida spp., Aspergillus spp., and Penicillium spp. that were detectable by nested PCR with these susceptibility primers. The temperature conditions and number of cycles were the same as in the first PCR. Species were identified in any positive PCR products using the same methods as those used to identify bacteria. The positive controls for bacterial PCR were 100 CFU/ml of Staphylococcus aureus ATCC29213, 500 CFU/ml of Candida albicans JCM1542, 500 CFU/ml of Candida glabrata JCM1539, and 500 CFU/ml of Aspergillus fumigatus JCM1617. The negative control was nuclease-free water. When these positive and negative controls did not work as expected, we considered the assay invalid. We validated the bacterial and fungal PCR using 18 strains of 9 bacteria and 26 strains of 13 fungi (data not shown). The sensitivity of detecting fungus was 100 CFU/ml while that for bacteria was 50 CFU/ml. Non-neutropenic fever due to engraftment syndrome (all cases manifested regional skin eruption and a slight CRP elevation, which might include the symptom of GVHD in some cases). identified by the molecular methods, although the detection timings of BC and PCR were slightly different. Seven of 10 patients developed fever during neutropenic status after ASCT (Figure 1 ). Bacteria were detected by PCR in samples taken from 6 of these patients (patients 4, 5, 7, 8, 9 and 10) . However, the remaining patient (patient 6) showed no molecular evidence of bacterial infection despite the presence of fever. Five of the 6 febrile patients showing bacterial PCR-positive results were manageable with empirical antibiotic therapies using broad-spectrum β-lactam plus glycopeptide without disclosure of the DNA data ( Table 2 ). Among them, patient 7 followed a complicated clinical course, but the PCR results still did not need to be disclosed. At first, S. maltophilia was isolated by BC on day 12 during an empirical treatment with MEPM and VCM; thus, MEPM was changed to pazufloxacin (PZFX) plus minocycline. PCR detection of this bacterium continued (days 14 and 19) despite its disappearance from BC (day 13), and Staphylococcus epidermidis was additionally identified by PCR on day 19. However, the antibacterial therapy eventually contributed to clinical improvement. These repeated PCR detections could be explained by the levels of bacteria undetectable by BC or by already dead bacteria, and the detection of S. epidermidis may represent contamination due to normal skin commensals introduced during blood collection. In the case for which the PCR results were disclosed (patient 8), a high fever and CRP elevation developed on day 11 during empiric DRPM and VCM therapy, and we changed DRPM to PZFX plus clindamycin to cover anaerobes. But, as the fever continued, DNA data were at last disclosed to the physicians. PCR analyses on days 8, 11 and 12 showed multiple species, but F. nucleatum had been identified on day 6; thus, ampicillin sulbactam was added on day 13 with a successful outcome. F. nucleatum may have been among the multiple species detected by PCR. Even in afebrile cases, bacteria were also detected by PCR in 5 samples from 3 patients (days 0 and 22 in patient 1, days 10 and 17 in patient 2, and day 1 in patient 5). These cases did not present any clinical problems, but still needed empirical antibiotic therapy for the symptoms of suspected infections.
Results
Molecular Detection of Bacteria
Molecular Detection of Fungi
Fifty-four PB samples from 10 patients were analyzed by fungal PCR (Figure 1 (Table 3) . No fungi were isolated from BC of any PB samples. The fungal PCR-positive cases were manageable without disclosure of the molecular data.
CT scans of patient 8 revealed several cavitary nodules in both lungs 12 days before ASCT. VRCZ had been given on suspicion of fungal infection, and these lesions disappeared just before preconditioning. The PCR data on day 0 identified Aspergillus fumigatus DNA, but at this time we were able to confirm the causal pathogen by PCR and to justify our VRCZ therapy. In patient 9, Candida crusei along with many other bacterial species were detected in a febrile situation on 
Discussion
In this study, we performed broad-range PCR assays to detect a wide spectrum of bacteria and fungi to compliment the drawbacks of BC and evaluated the clinical usefulness of this system for planning BSI treatment during the first month after ASCT. Although PCR analysis proved far more sensitive than BC for the detection of both bacteria and fungi, most cases with PCR-positive results were manageable with empirical antimicrobial therapy alone and without the DNA data. This indicates that our PCR assay did not directly contribute to BSIs management early after ASCT. However, the PCR data seemed to provide etiologically As for the origin of bacteria identified by PCR, it is noteworthy that more than half of the organisms were considered to have originated from the oral cavity. In patients receiving intensive chemotherapy, not only neutropenia, but also treatment-induced mucosal injury appears to be crucial for the development of BSIs, and causative pathogens can originate from the endogenous microbiota inhabiting the mouth and the gut of the patients [11] [12] . Furthermore, severe oral mucositis occurs quite often in ASCT recipients due to the adverse effects of preconditioning with TBI [13] and cytotoxic drugs, such as high-dose cyclophosphamide and/or cytarabin [11] , and the use of methotrexate containing GVHD prophylaxis [14] . Accordingly, BSIs due to orally derived organisms may develop more frequently in ASCT recipients than in patients receiving conventional chemotherapies. In addition, fluoroquinolone prophylaxis has been associated with an increased incidence of BSIs due to gram-positive bacteria, and oral viridans streptococci is one of among the most common blood stream isolates [15] [16], consistently with our observations. Orally derived bacteria appear to break into systemic circulation easily, because they do not pass through the major phagocytic system, such as the liver [17] , and tend to be detected in PB with unexpected frequency compared to intestinal bacteria, as shown in our study. Since oral management is reported to effectively decrease the severity of stomatitis during ASCT [18] [19] [20] , the same techniques should be evaluated for control of BSIs in ASCT recipients.
The other bacteria identified, E. faecalis [21] , S. epidermidis [22] , S. maltophilia [23] and MRSA [24] , have also been described as orally derived pathogens in immunocompromised hosts. Since we performed DNA analyses only on PB samples and not on samples from mouth mucosa, we could not confirm their oral origin. However, such an origin seemed unlikely, as the former 3 species were detected in patients lacking stomatitis. In our study, contamination by exogenous microbes was distinguishable in most cases by the identity of the species, frequency of detection, and clinical evaluation. Transitory appearance of S. epidermidis was likely to be originated from contamination from the skin [25] [26].
The present study also demonstrated that all cases showing gram-positive bacteria in PCR were effectively treated by empirical therapy with glycopeptides [8] . To our knowledge, there have been no reports in which the effectiveness of this antibacterial strategy was confirmed etiologically based on molecular data from ASCT recipients.
Even in afebrile patients, PCR-positive results for bacteria or fungi were obtained in some cases. All such cases received empirical antimicrobial treatments due to observation of signs or symptoms of infection prior to PCR detection.
Our findings suggest that preclinical or occult BSIs may continually occur in ASCT recipients regardless of the presence of fever. Further investigations are necessary to clarify the significance of the molecular identification of microor-ganisms in such cases.
In conclusion, although the molecular analyses did not directly contribute to manage BSI management early after ASCT, the DNA data were at least useful in elucidating the microbiological etiology of the BSIs. In addition, oral management appears to require a critical re-evaluation to reduce BSIs in ASCT recipients [18] [19] [20] [27] . However, as the main limitation of this study was the small number of cases examined, future large-scale studies will be required to validate our observations.
